

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
JULY 17, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Aegerion Pharmaceuticals, Inc.

File No. 001-34921 -- CF# 32170

Aegerion Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 2, 2015, as amended.

Based on representations by Aegerion Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.29	through November 5, 2024
Exhibit 10.31	through March 2, 2025
Exhibit 10.32	through March 2, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary